Page 1742 - Williams Hematology ( PDFDrive )

1716 Part XI: Malignant Lymphoid Diseases Chapter 105: Plasma Cell Neoplasms: General Considerations 1717

approaches. It will also be important to establish what degree of tumor 28. Cheng WJ, Glebov O, Bergsagel PL, Kuehl WM: Genetic events in the pathogenesis of
reduction has the highest prognostic significance. Extremely sensitive multiple myeloma. Best Pract Res Clin Haematol 20:571, 2007.
techniques might not necessarily provide better prognostic information 29. Chiecchio L, Dagrada GP, Protheroe RK, et al: Loss of 1p and rearrangement of MYC
are associated with progression of smoldering myeloma to myeloma: Sequential analy-
than somewhat less-sensitive techniques. sis of a single case. Haematologica 94:1024, 2009.
30. Hanamura I, Stewart JP, Huang Y, et al: Frequent gain of chromosome band 1q21
in plasma cell dyscrasias detected by fluorescence in situ hybridization: Incidence
REFERENCES increases from MGUS to relapse myeloma and is related to prognosis and disease pro-
gression following tandem stem-cell transplantation. Blood 108:1724, 2006.
1. Lindqvist EK, Goldin LR, Landgren O, et al: Personal and family history of 31. Rosinol L, Carrio A, Blade J, et al: Comparative genomic hybridization identifies two
immune-related conditions increase the risk of plasma cell disorders: A population variant of smoldering multiple myeloma. Br J Haematol 130:729, 2005.
based study. Blood 118:6284, 2011. 32. Anguiano A, Tuchman SA, Acharya C, et al: Gene expression profiles of tumor biology
2. Landgren O, Kyle RA, Pfeiffer RM, et al: Monoclonal gammopathy of undetermined provide a novel approach to prognosis and may guide the selection of therapeutic tar-
significance consistently precedes multiple myeloma: A prospective study. Blood 113:5412, gets in multiple myeloma. J Clin Oncol 27:4197, 2009.
2009. 33. Avet-Loiseau H, Gerson F, Magrangeas F, et al: Rearrangements of the c-MYC onco-
3. Weiss BM, Abadie J, Verma P, et al: A monoclonal gammopathy precedes multiple mye- gene are present in 15% of primary human multiple myeloma tumors. Blood 98:3082,
loma in most patients. Blood 113:5418, 2009. 2001.
4. Landgren O, Kyle RA, Hoppin JA, et al: Pesticide exposure and risk of monoclonal gam- 34. Walker BA, Wardell CP, Melchor L, et al: Intraclonal heterogeneity is a critical early
mopathy of undetermined significance in the agricultural health study. Blood 113:6386, event in the development of myeloma and precedes the development of clinical symp-
2009. toms. Leukemia 28:384, 2014.
5. Brown LM, Gridley G, Check D, Landgren O: Risk of multiple myeloma and mono- 35. Landgren O, Rajkumar SV, Pfeiffer RM, Kyle RA, Katzmann JA, Dispenzieri A, et al:
clonal gammopathy of undetermined significance among white and black male United Obesity is associated with an increased risk of monoclonal gammopathy of undeter-
States veterans with prior autoimmune, infectious, inflammatory and allergic disorders. mined significance (MGUS) among African-American and Caucasian women. Blood
Blood 111:3388, 2008. 116:1056, 2010.
6. Landgren O, Kristinsson SY, Goldin LR, et al: Risk of plasma cell and lymphoprolif- 36. Carson KR, Bates ML, Tomasson MH: The skinny on obesity and plasma cell myeloma:
erative disorders about 14621 first-degree relatives of 4458 patients with monoclonal A review of the literature. Bone Marrow Transplant 49:1009, 2014.
gammopathy of undetermined significance in Sweden. Blood 114:791, 2009. 37. Teras LR, Kitahara CM, Birmann BM, et al: Body size and multiple myeloma mortality:
7. Vachon CM, Kyle RA, Therneau TM, et al: Increased risk of monoclonal gammopathy A pooled analysis of 20 prospective studies. Br J Haematol 166:667, 2014.
in first-degree relatives of patients with multiple myeloma or monoclonal gammopathy 38. Murphy F, Kroll ME, Pirie K, et al: Body size in relation to incidence of subtypes of hae-
of undetermined significance. Blood 114:785, 2009. matological malignancy in the prospective Million Women Study. Br J Cancer 108:2390,
8. Grass S, Pruess KD, Ahlgrimm M, et al: Association of dominantly inherited hyper- 2013.
phosphorylated paraprotein target with sporadic and familial multiple myeloma and 39. Hofmann JN, Moore SC, Lim U, et al: Body mass index and physical activity at different
monoclonal gammopathy of undetermined significance: A case control study. Lancet ages and risk of multiple myeloma in the NIH-AARP diet and health study. Am J Epi-
Oncol 10:950, 2009. demiol 177:776, 2013.
9. Preuss KD, Pfreundschuh M, Fadle N, et al: Hyperphosphorylation of autoantigenic 40. Wallin A, Larsson SC: Body mass index and risk of multiple myeloma: A meta-analysis
targets of paraproteins is due to inactivations of PP2A. Blood 118:3340, 2011. of prospective studies. Eur J Cancer 47:1606, 2011.
10. Zwick C, Held G, Augh M, et al: Over one-third of African American MGUS and mul- 41. Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ: Overweight, obesity, and
tiple myeloma patients are carries of hyperphosphorylated paratarg-7, an autosomal mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med
dominantly inherited risk factor for MGUS/MM. Int J Cancer 135:934, 2014. 348:1625, 2003.
11. Fonseca R, Bailey RJ, Ahman, et al: Genomic abnormalities in monoclonal gammopa- 42. Dhodapkar MV: Adipokines in MM: Time to trim the fat. Blood 118:5716, 2011.
thy of undetermined significance. Blood 100:1417, 2002. 43. Birmann BM, Giovannucci EL, Rosner BA, Colditz GA: Regular aspirin use and risk of
12. Fonseca R, Barlogie B, Bataille R, et al: Genetics and cytogenetics of multiple myeloma: multiple myeloma: A prospective analysis in the health professionals follow up study
A workshop report. Cancer Res 64:1546, 2004. and nurses’ health study. Cancer Prev Res (Phila) 7:33, 2014.
13. Kuehl WM, Bergsagel PL: Multiple myeloma: Evolving genetic events and host interac- 44. Ding J, Yuan L, Huang RB, Chen G: Aspirin inhibits proliferation and induces apopto-
tions. Nat Rev Cancer 2:175, 2002. sis of multiple myeloma cells through regulation of Bcl-2 and Bax and suppression of
14. Kuehl WM, Bergsagel PL: Chromosome translocations in multiple myeloma. Oncogene VEGF. Eur J Haematol 93:329, 2014.
20:5611, 2001. 45. Alexander DD, Mink PJ, Adami HO, et al: Multiple myeloma: A review of epidemio-
15. Rajkumar SV, Kyle RA, Therneau TM, et al: Serum free light chain ratio is an indepen- logic literature. Int J Cancer 120:40, 2007.
dent risk factor for progression in monoclonal gammopathy of undetermined signifi- 46. Mohamed-Ali V, Goodrick S, Rawesh A, et al: Subcutaneous adipose tissue releases
cance. Blood 106:812, 2005. IL-6 but not tumor necrosis factor-alpha, in vivo. J Clin Endocrinol Metab 82:4196,
16. Perez-Persona E, Vidriales MB, Mateo G, et al: New criteria to identify risk of progres- 1997.
sion in monoclonal gammopathy of uncertain significance and smoldering multiple 47. Morgan GJ, Davies FE, Linet M: Myeloma aetiology and epidemiology. Biomed Phar-
myeloma based on multiparameter flow cytometry analysis of bone marrow plasma macother 56:223, 2002.
cells. Blood 110:2586, 2007. 48. Hsu WL, Preston DL, Soda M, et al: The incidence of leukemia, lymphoma and multiple
17. Cesana C, Klersy C, Barbarano L, et al: Prognostic factors for malignant transformation myeloma among atomic bomb survivors: 1950–2001. Radiat Res 179:361, 2013.
in monoclonal gammopathy of undetermined significance and smoldering multiply 49. Wang JX, Boice JD, Li BX, et al: Cancer among medical diagnostic x-ray workers in
myeloma. J Clin Oncol 20:1625, 2002. China. J Natl Cancer Inst 80:344, 1988.
18. Facon T, Menard FJ, Chaux JL, et al: Prognostic factors in low tumor mass asymptom- 50. Goedert JJ, Cote TR, Virgo P, et al: Spectrum of AIDS-associated malignant disorders.
atic multiple myeloma: A report on 91 patients. Am J Hematol 48:71, 1995. Lancet 351:1833, 1988.
19. Wisloff F, Andersen P, Andersson TR, et al: Incidence and follow up of asymptomatic 51. Grulich AE, Wan X, Law MG, et al: Risk of cancer in people with AIDS. AIDS 13:839,
multiple myeloma. Eur J Haematol 47:338, 1991. 1999.
20. Weber DM, Dimopoulos MA, Moulopoulos LA, et al: Prognostic features of asymp- 52. Duberg A, Nordstrom M, Torner A, et al: Non-Hodgkin’s lymphoma and other non-
tomatic multiple myeloma. Br J Haematol 97:810, 1997. hepatic malignancies in Swedish patient with hepatitis C virus infection. Hepatology
21. Alexanian R, Barlogie B, Dixon D: Prognosis of asymptomatic multiple myeloma. Arch 41:652, 2005.
Intern Med 148:1963, 1988. 53. Linet MS, Humphrrey RL, Mehl ES, et al: A case control and family study of WM.
22. Dimopoulos MA, Moulopoulos A, Smith T, et al: Risk of disease progression in asymp- Leukemia 7:1363, 1993.
tomatic multiple myeloma. Am J Med 94:57, 1993. 54. Giordano TP, Henderson L, Landgren O, et al: Risk of non-Hodgkin lymphoma and
23. Dimopoulos MA, Terpos E, Comenzo RL, et al: International myeloma working group lymphoproliferative precursor diseases in US veterans with hepatitis C virus. JAMA
consensus statement and guidelines regarding the current role of imaging techniques in 297:2010, 2007.
the diagnosis and monitoring of multiple myeloma. Leukemia 23:1545, 2009. 55. Koshiol J, Gridley G, Engels EA, et al: Chronic immune stimulation and subsequent
24. Kyle RA, Remstein ED, Therneau TM, et al: Clinical course and prognosis of smolder- Waldenström macroglobulinemia. Arch Intern Med 168:1903, 2008.
ing (asymptomatic) multiple myeloma. N Engl J Med 356:2582, 2007. 56. Kristinsson SY, Koshiol J, Goldin LR, et al: Immune related and inflammatory condi-
25. Dispenzieri A, Kyle RA, Katzmann JA, et al: Immunoglobulin free light chain ratio tions and risk of lymphoplasmacytic lymphoma or Waldenström macroglobulinemia. J
is an independent risk factor for progression of smoldering (asymptomatic) multiple Natl Cancer Inst 102:557, 2010.
myeloma. Blood 111:785, 2008. 57. Fine JM, Lambin P, Massari M, Leroux P: Malignant evolution of asymptomatic mono-
26. Landgren O: Monoclonal gammopathy of undetermined significance of smoldering clonal IgM after seven and fifteen years in two siblings of a patient with Waldenström’s
multiple myeloma: New insights into pathophysiology and epidemiology. Hematology macroglobulinemia. Acta Med Scand 211:237, 1982.
Am Soc Hematol Educ Program 2010:295, 2010. 58. McMaster ML, Goldin LR, Bai Y, et al: Genome wide linkage screen for Waldenstrom
27. Hallek M, Bergsagel PL, Anderson KC: Multiple myeloma: Increasing evidence for a macroglobulinemia susceptibility loci in high risk families. Am J Hum Genet 79:695,
multistep transformation process. Blood 91:3, 1998. 2006.

Kaushansky_chapter 105_p1707-1720.indd 1717 9/18/15 9:45 AM